Bivalirudin reduces bleeding rate in carotid stenting

Courtesy of Dr. Carlos Fava

bivalirudina-heparina-anticoagulantesBivalirudin has been shown to reduce bleeding in carotid stenting and maintain its efficacy. Even though carotid stenting has shown benefits, these remain unclear.

 

With this in mind, four studies were analyzed (one randomized) including 7,784 patients undergoing carotid stenting with unfractioned heparin vs. bivalirudin.

 

No difference was found between the groups across the different studies.

 

Bivalirudin was shown to reduce major bleeding rate with a relative risk (RR) of 0.53 (95% CI: 0.35-0.8; I2=0%) and minor bleeding RR of 0.41 (95% CI: 0.2-0.82; I2 =0%), with no difference in ischemic stroke, intracranial bleeding, infraction or mortality at 30 days.

 

Conclusion

Compared to unfractioned heparin, bivalirudin was associated with lower bleeding risk when used in carotid stenting.

 

Comment

The use of bivalirudin has shown this benefit in coronary PCI, but the transradial approach has also shown this benefit in PCI with unfractioned heparin.

 

In addition, bivalirudin significantly increases costs compared to unfractioned heparin.

 

Perhaps the use of the transradial approach (which several studies show as feasible and safe) neutralizes this benefit of bivalirudin, except for those cases that, for several reasons, should be done via femoral.  

 

Courtesy of Dr. Carlos Fava

 

Original Title: Hemorrhagic and Ischemic Outcomes of Heparin vs. Bivalirudin in Carotid Artery Stenting: A Meta-analysis of Studies.

Reference: Jad Omran, et; al. Catheterization and Cardiovascular Intervention 2017;88:746-753.


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

We are interested in your opinion. Please, leave your comments, thoughts, questions, etc., below. They will be most welcome.

More articles by this author

Patients at High Risk of Bleeding After Coronary Angioplasty: Are Risk Assessment Tools ARC-HBR and PRECISE-DAPT Useful?

Patients undergoing coronary stenting typically receive dual antiplatelet therapy (DAPT) for 6 to 12 months, consisting of a P2Y12 receptor inhibitor and aspirin. While DAPT...

ACC-2025 Congress Second Day Key Studies

BHF PROTECT-TAVI (Kharbanda RK, Kennedy J, Dodd M, et al.)The largest randomized  trial carried out across 33 UK centers between 2020 and 2024, assessing...

ACC 2025 | API-CAT: Reduced vs. Full Dose Extended Anticoagulation in Patients with Cancer Related VTE

The risk of cancer related recurrent venous thromboembolism (VTE) will drop over time, while bleeding risk will persist. At present, it is recommended we...

STRIDE: Semaglutide in Patients with Peripheral Arterial Disease and Type II Diabetes

Peripheral arterial disease (PAD) is a severe complication in patients with type II diabetes, primarily affecting peripheral vessels, especially below-the-knee (BTK) arteries. This condition...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

RACE Trial: Effect of Balloon Pulmonary Angioplasty and Riociguat on Right Ventricular Afterload and Function in Chronic Thromboembolic Pulmonary Hypertension

Even though pulmonary endarterectomy is the treatment of choice for chronic thromboembolic pulmonary hypertension (CTEPH), up to 40% of patients are not candidates because...

iFR- vs. FFR-Guided Coronary Revascularization: 5-Year Clinical Outcomes

The assessment of coronary stenosis using coronary physiology has become a key tool in guiding revascularization. The two most widely used techniques are fractional...

TAVR in Small Annuli: What Valve Should We Use?

One of the major challenges of severe aortic stenosis are patients with small aortic annuli, defined as ≤430 mm² aortic valve area. This condition...